drugset / Trial / NCT05617820

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

NCT05617820

Phase 3 Completed 1050 enrolled Teva Pharmaceuticals USA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.

Timeline

Start
2022-11-15
Primary completion
2024-03-15
Completion
2024-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 4 ug Intravenous

Indications

No indication recorded.